Please assess the completion status of the following clinical trial:

Trial Title: Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients ≥ 18 years of age~* Diagnosis of visual impairment exclusively due to ME secondary to CRVO~* BCVA score at Screening and Baseline between 73 and 19 letters Early Treatment Diabetic Retinopathy Study (ETDRS), inclusively (approximate Snellen chart equivalent of 20/40 and 20/400)~Exclusion Criteria:~* Uncontrolled blood pressure defined as systolic value of \> 160 mm Hg or diastolic value of \> 100 mm Hg at Screening or Baseline.~* Any active periocular or ocular infection or inflammation at Screening or Baseline in either eye~* Uncontrolled glaucoma at Screening or Baseline or diagnosed within 6 months before Baseline in either eye~* Use of any systemic antivascular endothelial growth factor (anti-VEGF) drugs within 6 months before Baseline (eg, sorafenib \[Nexavar®\], sunitinib \[Sutent®\], bevacizumab \[Avastin®\])

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab arm (Type: EXPERIMENTAL): Intravitreal injection with standard dose of 0.5 mg/0.05mL PRN

Based on this trial design, predict the completion outcome and termination type (if applicable).